Tag Archive for: Dr. Martina Schmitz

The oncgnostics managers together with Geneo Dx managers and colleagues.

Approval for cervical cancer screening test in the Chinese market expected in early 2020 / First contacts in Japan

Shanghai/Yokohama/Tokyo/Jena, 1 November 2019 –Our business partner in China, GeneoDx, is about to get approval to commercialise GynTect in the Chinese market. This issue was discussed at a business meeting with representatives from oncgnostics GmbH in Shanghai.

Our Chinese business partner GeneoDx, a SINOPHARM subsidiary, presented oncgnostics’ managing directors, Dr Martina Schmitz and Dr Alfred Hansel, in Shanghai with the results of their recently completed approval study for the National Medical Products Administration (NMPA) for the molecular biological test GynTect. The approval of GynTect for the Chinese market is expected in early 2020. The test allows reliable and rapid diagnosis of cervical cancer and its precancerous stages.

‘Our partners have conducted a study with approximately 1,300 samples. Results look very promising. We are optimistic that GeneoDx will receive approval for GynTect without any problems. Moreover, the study will be followed by high-ranking publications,’ states oncgnostics’ managing director Martina Schmitz.

Dr Alfred Hansel visited BioJapan in Yokohama, Japan. At the conference, he cultivated existing contacts, which he had made during a visit to MedTech Japan in Tokyo earlier this year. He also held discussions with other companies on the marketing opportunities of GynTect in Japan and other countries in Southeast Asia.

The Asian market is interesting for oncgnostics not only with regard to GynTect. International partnerships are also being sought for current pipeline projects, in particular the development of assays in the field of head and neck tumour diagnostics.

About oncgnostics:

Jena’s oncgnostics GmbH specialises in the early detection of cancer. Its tests detect changes that are characteristic of cancer cells’ DNA. Founded in 2012, the company launched GynTect in 2015. As part of its programme for the early detection of cervical cancer, the test clarifies whether cervical cancer or precancerous lesions are already present. In April 2017, GeneoDx and oncgnostics signed an exclusive license agreement for GynTect in China, Hong Kong, and Macau.

Oncgnostics GmbH is also conducting research into tests for the clarification of other types of cancer. Detailed information is available at www.oncgnostics.com.

About GynTect:

GynTect is a molecular biological test that identifies six areas of the human genome that are methylated only during the development of cancer cells. Thus, GynTect recognises malignant changes in patients.

Indien oncgnostics GmbH

From the 9 to the 16 In February, our managing director Dr Martina Schmitz travelled to India as a participant of the delegation trip ‘Thuringia goes India’. There she got an impression of the Indian market and made first contacts. The trip took place under the direction of Wolfgang Tiefensee, Thuringia’s Minister for Economic Affairs, Science and Digital Society.

From Pune to Mumbai

Dr Martina Schmitz faced a tight programme at four cities in only one week. From New Delhi to Pune, Coimbatore and finally Mumbai. Her itinerary started in the north and continued in the south of India, returning to the north again. Together with the other participants, our managing director visited medium-sized companies, and took part in various round tables and receptions, such as those organised by the Federation of Indian Chambers of Commerce and Industry (FICCI). Dr Martina Schmitz also visited two hospitals in Pune to have the Indian healthcare system explained to her.

Promising Contacts with Indian Companies

Representatives of Indian companies met representatives of Thuringian companies in the so-called round tables. Some of the meetings were organised in advance, but many contacts also came about spontaneously. ‘I was able to have some promising conversations’, says Dr Martina Schmitz, ‘now, back in Germany, these contacts should be checked and a follow-up should be agreed on.’

India: A Country Full of Contrasts

Dr Martina Schmitz was impressed by the different worlds that meet in India: ‘On the way to a company I drive along an alley full of people. Power cables are laid open next to the houses. There is rubbish on the street. Then I reach my destination, enter the building, and I find myself inside a glamorous office.’ Tradition and modernity also coexist closely in India. Not only during temple visits did the travellers get a Bindi, a dot pressed on their foreheads, but also during business appointments: ‘This trip provided me with a good insight of the Indian market. I am looking forward to strengthening the contacts I have established’, summarises Dr Martina Schmitz on the results of the India trip.